Anti-angiogenic strategies will be a revolution in lymphoma?

Leukemia Research

Volumn 34, Issue 4, 2010, Pages 552-

  Paydas, Semra ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; RITUXIMAB; THALIDOMIDE; VASCULOTROPIN A; VASCULOTROPIN C; VINCRISTINE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; B CELL LYMPHOMA; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; LARGE CELL LYMPHOMA; LETTER; LOW DRUG DOSE; LYMPHANGIOGENESIS; LYMPHOMA; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHANGIOGENESIS; LYMPHOMA; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 76749151775     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.09.023     Document Type: Letter

References (9)

1. Ribatti D. Lymphangiogenesis in haematological malignancies. Leuk Res 33 (2009) 753-755
2. Salven P., Lymbossaki A., Heikkila P., Sari H.S., Enholm B., Aase K., et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153 (1998) 103-108
3. Kudowaki I., Ichinohasama R., Harigae H., Ishizawa K., Okitsu Y., Kameoka J., and Sasaki T. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGFC. Br J Haematol 130 (2005) 869-877
4. Wrobel T., Mazur G., Dzie P., Jelen M., Szuba A., Kulickowski K., and Zabel M. Density of intranodal lymphatics and reactive lymph nodes. Folia Histochem Cytobiol 44 (2006) 43-47
5. Pazgal I., Boycov O., Shpilberg O., Okon E., and Bairey O. Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymphoma 48 (2007) 2213-2220
6. Paydas S., Ergin M., Erdogan S., and Seydaoglu G. Prognostic significance of EBV-LMP-1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res 32 (2008) 1424-1430
7. Paydas S., Ergin M., Seydaoglu G., Erdogan S., and Yavuz S. Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res March 13 (2009) [Epub ahead of print]
8. Ganjoo K.N., An C.S., Robertson M.J., Gordon L.I., Sen J.A., Weisenbach J., Li S., Weller E.A., Orazi A., and Horning S.J. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 47 (2006) 998-1005
9. Stopeck A.T., Unger J.M., Rimsza L.M., Bellamy W.T., Iannone M., Persky D.O., Leblanc M., Fisher R.I., and Miller T.P. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 50 (2009) 728-735